New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.92 2.18 +1.64%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 4.56% in Q3 FY26, the lowest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE36.9%18.9%7.0%5.1%
ROIC16.3%9.3%5.1%4.6%

Debt

Net debt is 5.30× a year’s EBITDA. Debt is 1.11× equity, against 1.22× in Q2 FY26.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.9×1.0×1.2×1.1×
Net debt / EBITDA4.9×−24.3×38.2×5.3×

Cash cycle, in days

Customers pay in 69 days, inventory is held 118 days and suppliers are paid in 96. Cash is tied up for 91 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle11612311791
Days to pay suppliers98827896
Days to be paid66686969

Per share, from Q4 FY25

Since Q4 FY25, per share: free cash flow has grown 20.9%; revenue has grown 5.07%; book value has fallen 13.5%.

Free cash flowRevenueBook value
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Free cash flow1.0×1.2×1.3×1.2×
Revenue1.0×1.0×1.0×1.1×
Book value1.0×0.9×0.8×0.9×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

36.86% 18.94% 6.97% 5.07%
Piotroski F-Score
4 4 4 4
ROA
14.37% 7.33% 2.57% 1.87%
ROIC
16.28% 9.33% 5.08% 4.56%
Return on Tangible Assets
45.07% 26.67% 9.15% 6.81%
Average Days of Receivables
66.11 67.76 68.89 69.04
Free Cash Flow per Share
4.94 5.71 6.50 5.97
Free Cash Flow
12,360.00 14,115.00 16,063.00 14,746.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026